繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

USPTO Grants Notice Of Allowance For Additional Patent On IceCure's Novel 'Cryogenic Pump' Technology, Reinforcing Co's Global IP Leadership in Cryoablation Technologies

2024-08-28 20:32

  • Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields
  • Over 50patents issued and allowed worldwide for IceCure's platform cryoablation technology

CAESAREA, Israel, Aug. 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a continuation application based on the Company's issued patent titled "Cryogen Pump". The original patent, which was also issued by the European Patent Office and the Japan Patent Office, as well as the continuation, will be in effect until 2041.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。